| Not Yet Recruiting | Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic T NCT02802423 | BioLite, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negati NCT07458204 | Institut Jean-Godinot | Phase 2 |
| Not Yet Recruiting | Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC NCT06396754 | Institute of Cancer Research, United Kingdom | — |
| Not Yet Recruiting | Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunothera NCT07357948 | Institut Curie | N/A |
| Not Yet Recruiting | Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype NCT07341867 | Andrew Hantel, MD | Phase 1 |
| Not Yet Recruiting | Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer NCT07528768 | AntiCancer Research Jamaica | Phase 2 |
| Recruiting | Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance NCT04861077 | University of Alabama at Birmingham | EARLY_Phase 1 |
| Not Yet Recruiting | Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Usi NCT07478705 | Sunnybrook Health Sciences Centre | N/A |
| Not Yet Recruiting | GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours NCT07297667 | Canadian Cancer Trials Group | Phase 1 |
| Not Yet Recruiting | Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer NCT07217990 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After NCT07486687 | The Netherlands Cancer Institute | Phase 3 |
| Not Yet Recruiting | Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients NCT07300475 | Washington University School of Medicine | Phase 1 |
| Recruiting | A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Ca NCT07533123 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 |
| Not Yet Recruiting | Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers NCT05806385 | Texas Tech University Health Sciences Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer NCT06224673 | Laura Huppert, MD, BA | Phase 2 |
| Not Yet Recruiting | Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituz NCT07134556 | MedSIR | Phase 2 |
| Recruiting | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types NCT07503808 | IDEAYA Biosciences | Phase 1 |
| Recruiting | Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution NCT07084571 | Royal Marsden NHS Foundation Trust | — |
| Recruiting | Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies NCT07340541 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Not Yet Recruiting | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy NCT07423117 | IntoCell, Inc | Phase 1 |
| Recruiting | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC NCT07510802 | Beijing Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) NCT07283692 | RenJi Hospital | Phase 2 |
| Not Yet Recruiting | ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC NCT07332975 | University of Pittsburgh | — |
| Not Yet Recruiting | NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-II NCT07178730 | West German Study Group | Phase 3 |
| Not Yet Recruiting | Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast NCT07419880 | Fudan University | Phase 2 |
| Recruiting | A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer NCT07281976 | Nanjing Leads Biolabs Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) NCT06225505 | Institut Curie | N/A |
| Not Yet Recruiting | Efficacy of Interleukin-2 in Triple Negative Breast Cancer NCT05821686 | Nova Scotia Health Authority | Phase 1 / Phase 2 |
| Recruiting | Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Ad NCT07401537 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumor NCT07318805 | Pfizer | Phase 1 |
| Recruiting | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors NCT07261631 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast NCT07525869 | Yonsei University | N/A |
| Recruiting | Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negat NCT06954480 | Queen Mary University of London | Phase 2 |
| Recruiting | Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients NCT06845319 | Medical University of South Carolina | Phase 2 |
| Recruiting | Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC NCT07066189 | Yale University | N/A |
| Recruiting | JS207 Combination Therapy in Triple-negative Breast Cancer NCT07045311 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Active Not Recruiting | Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer NCT07092254 | Daiichi Sankyo | — |
| Not Yet Recruiting | Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC NCT07007780 | Xijing Hospital | Phase 2 |
| Not Yet Recruiting | Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer NCT07139470 | Tianjin Medical University Cancer Institute and Hospital | Phase 1 / Phase 2 |
| Recruiting | A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs NCT06908928 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 |
| Recruiting | Triple Negative Breast Cancer and Celecoxib. Pilot Study NCT07104266 | Université de Sherbrooke | Phase 2 |
| Recruiting | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043 | AstraZeneca | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations NCT07038369 | Atavistik Bio, Inc | Phase 1 |
| Recruiting | A Study of LY4175408 in Participants With Advanced Cancer NCT07046923 | Eli Lilly and Company | Phase 1 |
| Recruiting | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187 | Dren Bio | Phase 1 |
| Not Yet Recruiting | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy NCT06976021 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Active Not Recruiting | Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer NCT06604858 | MedSIR | Phase 2 |
| Recruiting | Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer NCT06879704 | Centre Henri Becquerel | N/A |
| Recruiting | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With S NCT06682793 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Tripl NCT06926920 | Gilead Sciences | Phase 1 / Phase 2 |
| Recruiting | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies NCT07064018 | University of California, Irvine | Phase 1 / Phase 2 |
| Recruiting | A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-011 NCT06700070 | Pure Biologics S.A. | EARLY_Phase 1 |
| Recruiting | First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tu NCT06799065 | Accent Therapeutics | Phase 1 |
| Recruiting | Viscum Album for TNBC on Adjuvant Pembrolizumab NCT06920810 | Ilsan Cha hospital | Phase 4 |
| Recruiting | Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer NCT06291064 | University of Chicago | Phase 2 |
| Recruiting | TNBC Gut Microbiota During Neoadjuvant Treatment NCT06610097 | Scripps Health | N/A |
| Recruiting | Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patie NCT06690840 | European Institute of Oncology | Phase 2 |
| Not Yet Recruiting | Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients NCT06795503 | Fudan University | Phase 3 |
| Recruiting | Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage T NCT06078384 | UNICANCER | Phase 2 |
| Recruiting | Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer Wit NCT06238921 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Suspended | A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positiv NCT05989828 | University of Southern California | Phase 1 |
| Recruiting | A Study of Tetrathiomolybdate (TM) Plus Capecitabine NCT06134375 | Dartmouth-Hitchcock Medical Center | Phase 1 / Phase 2 |
| Recruiting | Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer NCT06631092 | NEC Bio B.V | Phase 1 / Phase 2 |
| Recruiting | Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC NCT06817525 | Henan Cancer Hospital | Phase 2 |
| Recruiting | Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SA NCT06358573 | Swiss Cancer Institute | Phase 2 |
| Recruiting | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers NCT06562192 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT) NCT06349512 | Institut Curie | N/A |
| Recruiting | NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT- NCT06081244 | West German Study Group | Phase 3 |
| Recruiting | A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. NCT06371274 | First Affiliated Hospital of Zhejiang University | N/A |
| Recruiting | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors NCT06617169 | Monopar Therapeutics | Phase 1 |
| Recruiting | Microbiome Immunotherapy Neoadjuvant Assessment NCT06709651 | University College Cork | — |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients NCT06353997 | Providence Health & Services | Phase 2 |
| Recruiting | A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha NCT06547840 | Epsilogen Ltd | Phase 1 |
| Not Yet Recruiting | Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment NCT06497322 | University Hospital of Cologne | N/A |
| Recruiting | Breast Cancer PSMA PET NCT06586047 | Ahmad Shariftabrizi | EARLY_Phase 1 |
| Active Not Recruiting | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Co NCT06449222 | BioNTech SE | Phase 2 |
| Recruiting | Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Pa NCT06225284 | National Taiwan University Hospital | Phase 2 |
| Recruiting | Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer w NCT06538896 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer NCT06460298 | ProDa BioTech, LLC | Phase 1 / Phase 2 |
| Recruiting | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies NCT06577987 | Circle Pharma | Phase 1 |
| Active Not Recruiting | FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-neg NCT06519370 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metas NCT06471205 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC NCT06533384 | Guangdong Provincial People's Hospital | Phase 3 |
| Recruiting | A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Canc NCT06492005 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 |
| Recruiting | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer NCT05485766 | Okayama University | Phase 2 |
| Recruiting | BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Ca NCT07108309 | Biocad | Phase 2 |
| Recruiting | SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers NCT05846789 | Kathy Miller | Phase 2 |
| Recruiting | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab NCT06371807 | Fundacao Champalimaud | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer NCT06407310 | Tel Aviv Medical Center | Phase 2 |
| Withdrawn | Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) NCT06246786 | Virginia G. Kaklamani | EARLY_Phase 1 |
| Recruiting | Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells NCT06347068 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Recruiting | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advan NCT06382142 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors NCT06399757 | Apollo Therapeutics Ltd | Phase 1 / Phase 2 |
| Withdrawn | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures NCT06084689 | Institut Bergonié | Phase 2 |
| Recruiting | Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy NCT06435351 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Not Yet Recruiting | Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer NCT06448169 | Shandong University | — |
| Recruiting | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors NCT06337084 | Monopar Therapeutics | Phase 1 |
| Recruiting | Breast Cancer Evolution During Neoadjuvant Systemic Therapy NCT06681064 | Royal Marsden NHS Foundation Trust | — |
| Recruiting | Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carbopla NCT06318897 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatmen NCT06451497 | Zumutor Biologics Inc. | Phase 1 |
| Recruiting | Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer NCT06355037 | Fudan University | Phase 2 |
| Completed | Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer NCT06355024 | Fudan University | Phase 2 |
| Terminated | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NCT06299163 | Numab Therapeutics AG | Phase 1 |
| Active Not Recruiting | ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC NCT06351332 | Filipa Lynce, MD | Phase 1 / Phase 2 |
| Recruiting | PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC NCT06245889 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Neg NCT06367088 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Enrolling By Invitation | VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study NCT06409221 | Concr | — |
| Recruiting | Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Ca NCT06182306 | Ourotech, Inc. | — |
| Completed | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors NCT06273852 | Pure Biologics S.A. | EARLY_Phase 1 |
| Not Yet Recruiting | Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical Trials NCT05769491 | Power Life Sciences Inc. | — |
| Active Not Recruiting | Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer NCT06175390 | Institut Curie | Phase 2 |
| Recruiting | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies NCT06150664 | Compass Therapeutics | Phase 1 |
| Recruiting | Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer NCT06220214 | Alison Stopeck | EARLY_Phase 1 |
| Active Not Recruiting | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors NCT06238479 | Eli Lilly and Company | Phase 1 |
| Enrolling By Invitation | Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies NCT06646263 | Institute of Applied Biosciences | — |
| Recruiting | A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metasta NCT06279364 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 3 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negativ NCT06202313 | Shengjing Hospital | Phase 2 |
| Recruiting | A Study of Pembrolizumab and Cryoablation in People With Breast Cancer NCT06246968 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Not Yet Recruiting | Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Brea NCT06229067 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Active Not Recruiting | Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer NCT06418126 | Centre Paul Strauss | N/A |
| Terminated | PRO1107 in Patients With Advanced Solid Tumors NCT06171789 | Genmab | Phase 1 / Phase 2 |
| Recruiting | Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery NCT06281210 | European Institute of Oncology | N/A |
| Active Not Recruiting | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid NCT06084481 | AbbVie | Phase 1 |
| Recruiting | Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemoth NCT06441240 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer NCT05902988 | Volastra Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in NCT06022029 | OncoNano Medicine, Inc. | Phase 1 |
| Terminated | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies NCT06052852 | Bolt Biotherapeutics, Inc. | Phase 1 |
| Recruiting | Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative NCT05552001 | UNICANCER | Phase 3 |
| Recruiting | Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment NCT06087120 | Gene Solutions | — |
| Unknown | A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative NCT04914390 | Sichuan Provincial People's Hospital | Phase 2 |
| Withdrawn | Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemothe NCT05809895 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Lu NCT05954442 | Fudan University | Phase 3 |
| Recruiting | A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) NCT05809752 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Sol NCT05983432 | SystImmune Inc. | Phase 1 |
| Not Yet Recruiting | T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients NCT05953168 | Fudan University | Phase 2 |
| Withdrawn | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metasta NCT05255666 | Washington University School of Medicine | Phase 2 |
| Recruiting | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies NCT05955105 | Innolake Biopharm | Phase 1 / Phase 2 |
| Recruiting | Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC NCT06955156 | QIAO LI | Phase 2 |
| Not Yet Recruiting | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Br NCT05843292 | Shanghai Jiao Tong University School of Medicine | Phase 4 |
| Recruiting | CTS2190 Phase I /II Clinical Study in Patients NCT06224387 | CytosinLab Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS NCT05909332 | Fudan University | Phase 3 |
| Recruiting | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer NCT05491083 | National University Hospital, Singapore | Phase 1 / Phase 2 |
| Recruiting | Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC) NCT05722795 | Vastra Gotaland Region | N/A |
| Unknown | Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer NCT05872412 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 2 |
| Terminated | A Biomarker Screening Protocol for Participants With Solid Tumors NCT05891197 | Lyell Immunopharma, Inc. | — |
| Recruiting | Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like NCT05763992 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Active Not Recruiting | Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-n NCT07018427 | Peking University Cancer Hospital & Institute | — |
| Withdrawn | Implantable Microdevice for TNBC - Pilot Study NCT05774886 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breas NCT05806060 | Fudan University | Phase 3 |
| Recruiting | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies NCT05783622 | Janux Therapeutics | Phase 1 |
| Recruiting | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer NCT05020860 | Baylor Breast Care Center | Phase 2 |
| Completed | Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint A NCT05730010 | Indiana University | — |
| Recruiting | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid T NCT05746897 | Hefei TG ImmunoPharma Co., Ltd. | Phase 1 |
| Recruiting | FUSCC Refractory TNBC Platform Study (FUTURE2.0) NCT05749588 | Fudan University | Phase 2 |
| Recruiting | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Adv NCT05760378 | Fudan University | Phase 3 |
| Terminated | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours NCT05714553 | NuCana plc | Phase 1 / Phase 2 |
| Unknown | Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer NCT05910710 | Samsung Medical Center | — |
| Unknown | A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Com NCT05670925 | Fudan University | Phase 2 |
| Recruiting | PRE-I-SPY Phase I/Ib Oncology Platform Program NCT05868226 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Completed | Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED NCT05520723 | MedSIR | Phase 2 |
| Active Not Recruiting | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer NCT05492682 | Valo Therapeutics Oy | Phase 1 |
| Unknown | AMT-151 in Patients With Selected Advanced Solid Tumours NCT05498597 | Multitude Therapeutics Inc. | Phase 1 |
| Recruiting | Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer NCT05528133 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Plat NCT05916755 | Vall d'Hebron Institute of Oncology | — |
| Unknown | A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Canc NCT05692661 | Shanghai Proton and Heavy Ion Center | Phase 1 |
| Recruiting | Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Intere NCT05404321 | Centre Francois Baclesse | — |
| Unknown | The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic NCT05680662 | Ministry of Health, Saudi Arabia | EARLY_Phase 1 |
| Recruiting | Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast NCT05475678 | Zhenzhen Liu | Phase 2 |
| Recruiting | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With NCT05633654 | Gilead Sciences | Phase 3 |
| Recruiting | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366 | Genmab | Phase 1 / Phase 2 |
| Recruiting | Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC NCT05645380 | University of Kansas Medical Center | Phase 2 |
| Unknown | A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC Wi NCT05556200 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Active Not Recruiting | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas NCT05565417 | Immunitas Therapeutics | Phase 1 / Phase 2 |
| Recruiting | LAG3 Expression in Triple Negative Breast Cancer NCT06259162 | Samsung Medical Center | N/A |
| Active Not Recruiting | Combination of Olaparib and Navitoclax in Women with HGSC and TNBC NCT05358639 | Sunnybrook Health Sciences Centre | Phase 1 |
| Recruiting | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negati NCT05447702 | West China Hospital | Phase 2 |
| Recruiting | Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast C NCT04947189 | St Vincent's Hospital, Sydney | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Unknown | Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Pa NCT05174832 | Fudan University | Phase 2 |
| Recruiting | Cardiac Outcomes With Near-Complete Estrogen Deprivation NCT05309655 | Duke University | N/A |
| Unknown | Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency NCT05461690 | Zhejiang Cancer Hospital | Phase 2 |
| Withdrawn | Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer NCT04268693 | George Washington University | — |
| Withdrawn | Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women NCT04291950 | University of Arizona | — |
| Recruiting | DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer NCT05504707 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer NCT05550415 | Indonesia University | Phase 2 |
| Recruiting | A Study of XMT-1660 in Participants With Solid Tumors NCT05377996 | Mersana Therapeutics | Phase 1 |
| Unknown | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors NCT05453825 | OncXerna Theraputics, Inc. | Phase 2 |
| Unknown | Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label NCT05390476 | wang shusen | Phase 2 |
| Active Not Recruiting | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab NCT05382286 | Gilead Sciences | Phase 3 |
| Active Not Recruiting | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreat NCT05382299 | Gilead Sciences | Phase 3 |
| Active Not Recruiting | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cance NCT05460273 | AstraZeneca | Phase 1 / Phase 2 |
| Unknown | A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or C NCT05438706 | Fudan University | Phase 2 |
| Withdrawn | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cance NCT03872505 | Cedars-Sinai Medical Center | Phase 2 |
| Recruiting | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients NCT04638751 | Persephone Biosciences | — |
| Recruiting | Reverse Triple Negative Immune Resistant Breast Cancer NCT05076682 | Fudan University | Phase 2 |
| Active Not Recruiting | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer NCT05451849 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Completed | Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients NCT05632848 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-n NCT05347134 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 3 |
| Terminated | Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment NCT05435352 | Ourotech, Inc. | — |
| Recruiting | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers NCT05403554 | Light Chain Bioscience - Novimmune SA | Phase 1 |
| Recruiting | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760 | Memgen, Inc. | Phase 1 |
| Completed | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients NCT05253053 | TransThera Sciences (Nanjing), Inc. | Phase 1 / Phase 2 |
| Recruiting | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer NCT05329532 | Scancell Ltd | Phase 1 / Phase 2 |
| Recruiting | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastat NCT05296564 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Terminated | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid NCT05252390 | Nuvation Bio Inc. | Phase 1 |
| Terminated | A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451 | Lyell Immunopharma, Inc. | Phase 1 |
| Completed | Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast NCT05340413 | SOLTI Breast Cancer Research Group | Phase 2 |
| Terminated | Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer NCT05300958 | Sun Yat-sen University | Phase 2 |
| Recruiting | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in NCT05078047 | UNICANCER | Phase 3 |
| Unknown | Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (H NCT05288127 | University of Malaya | Phase 2 |
| Completed | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer NCT05112536 | G1 Therapeutics, Inc. | Phase 2 |
| Recruiting | ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab NCT05082259 | Institute of Cancer Research, United Kingdom | Phase 1 |
| Withdrawn | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select NCT05234606 | Silverback Therapeutics | Phase 1 / Phase 2 |
| Completed | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in NCT05082610 | Hummingbird Bioscience | Phase 1 |
| Recruiting | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies NCT05627960 | A&G Pharmaceutical Inc. | Phase 1 |
| Terminated | A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastat NCT05134194 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 |
| Recruiting | Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic NCT05192798 | The First Affiliated Hospital of Bengbu Medical University | Phase 2 |
| Active Not Recruiting | Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast NCT05181462 | Cantargia AB | Phase 1 / Phase 2 |
| Withdrawn | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC NCT05233696 | University of Colorado, Denver | Phase 2 |
| Active Not Recruiting | Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer NCT05169853 | Ain Shams University | — |
| Completed | Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) NCT06618014 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors NCT05145907 | TJ Biopharma Co., Ltd. | Phase 2 |
| Recruiting | Study of Screening Brain MRIs in Stage IV Breast Cancer NCT05115474 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Terminated | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastat NCT04958785 | Gilead Sciences | Phase 2 |
| Terminated | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer NCT05113966 | G1 Therapeutics, Inc. | Phase 2 |
| Completed | Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity NCT05111067 | Nova Scotia Health Authority | — |
| Terminated | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With NCT04916002 | Regeneron Pharmaceuticals | Phase 2 |
| Unknown | MicroRNA Profiles in Triple Negative Breast Cancer NCT04771871 | University College Hospital, Ibadan | Phase 2 |
| Recruiting | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors NCT05037825 | VastBiome | — |
| Active Not Recruiting | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours NCT05057013 | Cancer Research UK | Phase 1 / Phase 2 |
| Terminated | A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC NCT05336721 | Chipscreen Biosciences, Ltd. | Phase 2 |
| Completed | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid NCT05001347 | I-Mab Biopharma US Limited | Phase 2 |
| Completed | Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer NCT07143097 | Beni-Suef University | Phase 2 |
| Recruiting | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Hea NCT05005403 | AbbVie | Phase 1 |
| Unknown | Asian Multicenter Prospective Study of ctDNA Sequencing NCT05099978 | National Cancer Center, Japan | — |
| Recruiting | Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patient NCT04677816 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Meta NCT04690855 | Mylin A. Torres, MD | Phase 2 |
| Unknown | A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advan NCT05068141 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Terminated | Sitravatinib in Metastatic Breast Cancer NCT04123704 | Xiang Zhang | Phase 2 |
| Completed | Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Can NCT04758780 | Institut Cancerologie de l'Ouest | Phase 2 |
| Completed | The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC NCT04877821 | Guangdong Provincial People's Hospital | Phase 2 |
| Recruiting | A Beta-only IL-2 ImmunoTherapY Study NCT05086692 | Medicenna Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple NCT04849364 | Bryan Schneider, MD | Phase 2 |
| Suspended | Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment NCT04803084 | Laura Kennedy | — |
| Terminated | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors NCT04577963 | Hutchmed | Phase 1 / Phase 2 |
| Recruiting | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 NCT04787042 | Simcha IL-18, Inc. | Phase 1 / Phase 2 |
| Withdrawn | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With NCT04602117 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Unknown | A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC NCT05103917 | Abbisko Therapeutics Co, Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer NCT04837209 | Massachusetts General Hospital | Phase 2 |
| Recruiting | Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer NCT04790305 | Fudan University | Phase 4 |
| Unknown | Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Can NCT04907344 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 / Phase 3 |
| Completed | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) NCT04925284 | Exelixis | Phase 1 |
| Unknown | Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients NCT04502680 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Unknown | Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negat NCT04913571 | Fudan University | Phase 2 |
| Terminated | Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer NCT04095689 | The Methodist Hospital Research Institute | Phase 2 |
| Terminated | BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) NCT04296942 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Exosome as the Prognostic and Predictive Biomarker in EBC Patients NCT05955521 | Samsung Medical Center | N/A |
| Recruiting | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Tripl NCT04683679 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer NCT04722978 | Sun Yat-Sen University Cancer Center | Phase 3 |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Active Not Recruiting | CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Can NCT04807192 | Centre Hospitalier Universitaire Vaudois | Phase 2 |
| Recruiting | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors NCT03915678 | Institut Bergonié | Phase 2 |
| Unknown | Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer NCT05302778 | University of Milano Bicocca | — |
| Completed | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid NCT04742959 | TransThera Sciences (Nanjing), Inc. | Phase 1 / Phase 2 |
| Unknown | PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC NCT04809779 | First Affiliated Hospital, Sun Yat-Sen University | Phase 2 |
| Withdrawn | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advance NCT04464967 | NKGen Biotech, Inc. | Phase 1 / Phase 2 |
| Terminated | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX T NCT04770272 | Palleos Healthcare GmbH | Phase 2 |
| Terminated | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid NCT04725331 | Transgene | Phase 1 / Phase 2 |
| Terminated | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) NCT04726332 | Exelixis | Phase 1 |
| Recruiting | Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast C NCT04768426 | Stanford University | Phase 2 |
| Completed | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors NCT04580485 | Incyte Corporation | Phase 1 |
| Completed | Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTO NCT04118062 | Institut Curie | N/A |
| Unknown | Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer NCT04745975 | Fudan University | Phase 2 |
| Recruiting | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignanc NCT04282044 | BioEclipse Therapeutics | Phase 1 |
| Completed | Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative NCT06965361 | Ziauddin University | — |
| Active Not Recruiting | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) NCT04443348 | Laura M. Spring, MD | Phase 2 |
| Completed | A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants NCT04613674 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Active Not Recruiting | Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Bre NCT04438681 | Centre Jean Perrin | — |
| Active Not Recruiting | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer NCT04331067 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer NCT04494958 | Fundacion Oncosur | Phase 1 / Phase 2 |
| Unknown | CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC NCT04457700 | Peking University | — |
| Unknown | Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy NCT04582955 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Terminated | A Study of PY314 in Subjects With Advanced Solid Tumors NCT04691375 | Ikena Oncology | Phase 1 |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer NCT04595565 | GBG Forschungs GmbH | Phase 3 |
| Completed | Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer NCT04464174 | MedSIR | Phase 2 |
| Terminated | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) NCT04504916 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC NCT04408118 | MedSIR | Phase 2 |
| Completed | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chem NCT04584112 | Hoffmann-La Roche | Phase 1 |
| Terminated | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic NCT04260802 | Ocellaris Pharma, Inc. | Phase 1 / Phase 2 |
| Unknown | Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer NCT04452370 | Chinese Academy of Medical Sciences | Phase 2 |
| Withdrawn | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in P NCT03982173 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Active Not Recruiting | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors NCT04432857 | Adlai Nortye Biopharma Co., Ltd. | Phase 1 |
| Terminated | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors NCT04442126 | Numab Therapeutics AG | Phase 1 / Phase 2 |
| Terminated | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer NCT04461600 | Ayala Pharmaceuticals, Inc, | Phase 2 |
| Recruiting | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer NCT04360941 | Royal Marsden NHS Foundation Trust | Phase 1 |